$IKT
Inhibikase Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$1.64
▼-0.91%-$0.015
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateInhibikase Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is IKT down today? It is at $1.64 (-0.91%), and our scanner flagged it 37 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment IKT spikes, and full due diligence on IKT — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $IKT 37 times in the last 30 days. Create a free account to track $IKT, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on IKT from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for IKT today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalyst“expect,” “intend,” “estimate,” “anticipate,” “project,” “target,” “forecast,” “aim,” "should," “will,” "may”, “continue”,Reported PAH: Orphan Disease with ~30% 5-YearReported 2025 $8.3 Billion* AntiproliferativesReported ($3.94B) Endothelin Pathway ($2.53B) Vasodilators $3.94B $0.42B $1.4B $2.53B Sotatercept - subcutaneos injection Activin Signaling ($1.44B) Antiproliferatives US sales of sotatercept expected to reach $2–$2.5 Billion in 2026 and continue, from the latest SEC filing. Read it →* Institutional ownership was unavailable, so float is insider-deduped only.
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on IKT from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for IKT today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
IKT last traded at $1.64, down 0.91% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Inhibikase Therapeutics, Inc. Common Stock (IKT) is next expected to report earnings on Friday, November 13, 2026, about 25 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The IKT Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged IKT 37 times in the last 30 days.
IKT (Inhibikase Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $230M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge IKT for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$IKT discussion
Sign in to ask a question or join the discussion.